“Bifidobacterium breve Bif195 protects against small intestinal damage caused by Acetylsalicylic Acid in healthy volunteers’ is a clinical trial that demonstrates the probiotic strain, Bif195, strengthens the defense against gut damage caused by regular use of aspirin.
“Gastroenterology is the leading journal within the field of gut and gastro health and we are delighted that this study has been accepted by such a highly reputed journal. The publication of the clinical study is a crucial step in the process towards commercialization of this strain as a new dietary supplement. Our end goal is to bring a solution that supports the defense against damage to the gut,” says Thomas Riis Jensen, head of commercial development in Human Health.
Intestinal damage caused by regular use of aspirin
The daily intake of low-dose aspirin can reduce the risk of heart disease and is taken by approximately 40 million people in the US alone1. However, the regular use of aspirin can have several side effects. Almost half of these 40 million people have tissue damage in the gut, including ulcers2. There is currently no product on the market that shows a documented scientific effect of helping to protect against this.
In a proprietary consumer survey on aspirin users, 50% of respondents voiced concern about gut-related side effects, including gastrointestinal ulcers, upset stomach and abdominal pain3.
New probiotic strain can protect the intestine
In this randomized placebo-controlled clinical trial with healthy volunteers, the results show that daily oral intake of Chr. Hansen’s specially selected strain, Bif195, can help protect against intestinal damage induced by aspirin.